Fresenius Medical Care AG & Co. KGaA Oliver Maier Else-Kr ner-Str.1 Phone: + 49 6172 609 2601 61352 Bad Homburg Fax: + 49 6172 609 2301 Germany www.fmc-ag.com North America: Terry L. Morris Phone: + 1 800 948 25

Fresenius Medical Care Reports Very Strong

Quarter and Full Year Results; Another Record

Year expected for 2012

4th Quarter 2011 Summary:

Full Year 2011 Summary:

Bad Homburg, Germany - Fresenius

Medical Care AG & Co. KGaA (the "company" or "Fresenius Medical Care";

Frankfurt Stock Exchange: FME / New York Stock Exchange: FMS), the world's largest provider of dialysis products and services,

today announced its results for the fourth quarter and full year of 2011.

Net revenue for the fourth quarter of

2011 increased by 5% to $3,323 million

(+6% at constant currency) compared to the fourth quarter of 2010. Organic revenue growth worldwide was 3%. Dialysis services

revenue grew by 3% to $2,435 million (+4% at constant currency) and dialysis product revenue increased by 9% to $888 million

(+10% at constant currency).

North America revenue for the fourth

quarter of 2011 increased by 1% to $2,096 million including the impact of the new Medicare end-stage renal disease prospective

payment system in the United States. Dialysis services revenue increased by 1% to $1,882 million with a same market growth of 3%.

Average revenue per treatment for U.S. clinics decreased to $351 in the fourth quarter of 2011 compared to $355 for the corresponding

quarter in 2010 reflecting the implementation of the new prospective payment system. Dialysis product revenue increased

by 2% to $214 million, mainly as a result of increased sales of hemodialysis products partially offset by lower pricing

of renal pharmaceuticals.

International revenue increased by 12%

to $1,223 million (+14% at constant currency). Organic revenue growth was 8%. Dialysis services revenue increased by 13% to $553

million (+16% at constant currency). Dialysis product revenue increased by 11% to $669 million

and increased by 12% at constant currency, mainly driven by higher sales of peritoneal dialysis products, dialysis machines, dialyzers,

products for acute care treatments and renal pharmaceuticals.

Operating income (EBIT) for the fourth

quarter of 2011 increased by 9% to $587 million compared to $539 million in the fourth quarter of 2010. This resulted in an operating

margin of 17.7% for the fourth quarter of 2011 compared to 17.0% for the corresponding quarter in 2010.

In North America, the operating margin increased

from 17.9% in the fourth quarter of 2010 to 19.1% in the fourth quarter of 2011. This increase was favorably influenced by the

development of pharmaceutical costs. Average costs per treatment for U.S. clinics decreased to $279 in the fourth quarter of 2011

compared to $287 for the corresponding quarter in 2010.

In the International segment, the operating

margin increased from 18.0% to 18.7% mainly due to favorable exchange rate effects and business growth in Asia-Pacific.

Net interest expense for the fourth

quarter of 2011 was $82 million compared to $74 million in the fourth quarter of 2010.

This development was mainly attributable to the higher level of financial debt as a result of the issuance of various tranches

of senior notes over the course of 2011.

Income tax expense was $165 million

for the fourth quarter of 2011 compared to $169 million in the fourth quarter of 2010. The effective tax rate decreased

to 32.7% from 36.3%.

Net income attributable to shareholders

of Fresenius Medical Care AG & Co. KGaA for the fourth quarter of 2011 was $310 million, an increase of 14% compared

to the corresponding quarter of 2010.

Earnings per share (EPS) for

the fourth quarter of 2011 rose by 14% to $1.02 per ordinary share compared to $0.90 for the fourth quarter of 2010. The weighted

average number of shares outstanding for the fourth quarter of 2011 was approximately 303.9 million shares

compared to 302.1 million shares for the fourth quarter of 2010. The increase in shares

outstanding resulted from stock option exercises in the past 12 months.

In the fourth quarter of 2011, the company

generated $497 million in cash from operations, an increase of 46% compared to the corresponding figure last year and representing

approximately 15% of revenue. The cash flow generation was supported by increased earnings, a favorable development of days sales

outstanding (DSO) compared to the fourth quarter of 2010 and lower income tax payments.

A total of $191 million in cash was spent for

capital expenditures, net of disposals. Free cash flow before acquisitions was $306 million compared to $173 million

in the fourth quarter of 2010. A total of $604 million in cash was spent for acquisitions, net of divestitures.

Free cash flow after acquisitions and divestitures was minus $298 million compared to minus $75 million in the fourth quarter

Net revenue for the full year 2011 increased

by 6% to $12,795 million (+5% at constant currency) compared to the full year 2010 and in line with our guidance. Organic revenue

growth was 2% in the full year 2011.

Operating income (EBIT) for the full

year 2011 increased by 8% to $2,075 million compared to $1,924 million in 2010, resulting in an operating margin of 16.2%

compared to 16.0% for the full year 2010.

Net interest expense for the full year

2011 was $297 million compared to $280 million in the same period of 2010.

Income tax expense for the full year

2011 was $601 million compared to $578 million in the same period in 2010, reflecting effective tax rates of 33.8%

and 35.2%, respectively.

For the full year 2011, net income attributable

to shareholders of Fresenius Medical Care AG & Co. KGaA was $1,071 million, up by 9% from the full year 2010 and in line with

In the full year 2011, earnings per ordinary

share rose by 9% to $3.54. The weighted average number of shares outstanding during the full

year 2011 was approximately 303.0 million.

Cash from operations during 2011 was

$1,446 million compared to $1,368 million for the same period in 2010, representing approximately 11% of revenue and

above our targeted 10% level.

A total of $570 million in cash was spent

for capital expenditures, net of disposals. Free cash flow before acquisitions for the full year 2011 was $876 million

compared to $861 million in the same period in 2010. A total of $1,775 million in cash was spent for acquisitions, net of

divestitures. Free cash flow after acquisitions and divestitures was minus $899 million compared to $243 million in the

Please refer to the attachments for a complete

overview on the fourth quarter and the full year 2011 and the reconciliation of non-GAAP financial measures included in this release

to the most comparable GAAP financial measures.

- Clinics - Treatments

As of December 31, 2011, Fresenius Medical

Care treated 233,156 patients worldwide, which represents a 9% increase compared to the previous year's figure. North

America provided dialysis treatments for 142,319 patients, an increase of 3%. Including 21 clinics managed by Fresenius Medical

Care North America, the number of patients in North America was 143,679. The International segment provided dialysis treatments

to 90,837 patients, an increase of 18% over the prior year's figure.

As of December 31, 2011, the company operated

a total of 2,898 clinics worldwide, which represents a 6% increase compared to the previous year's figure. The number

of clinics is comprised of 1,838 clinics in North America (1,859 including managed clinics), and 1,060 clinics in the International

segment, representing an increase of 2% and 13%, respectively.

During the full year 2011, Fresenius Medical

Care delivered approximately 34.39 million dialysis treatments worldwide. This represents an increase of 9% compared

to last year's figure. North America accounted for 21.61 million treatments, an increase of 4%. The International segment